SINTX Technologies Achieves First Human Implant of FDA-Cleared Silicon Nitride Foot and Ankle Device

SINTX Technologies (search)Search company has achieved a significant clinical milestone with the successful completion of the first-in-human surgical procedure using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. The procedure, performed on March 13, 2026, by Dr. Scott Carrington, DPM, FACFAS, at Emplify Health (search)Search term in La Crosse, Wisconsin, marks the company's entry into the foot and ankle reconstruction market and represents a critical step in commercializing its silicon nitride biomaterial platform.

The SINAPTIC system received U.S. FDA 510(k) clearance in October 2025 and integrates surgeon-informed design with SINTX's proprietary silicon nitride technology. This achievement positions the Salt Lake City-based company to compete in the multi-billion-dollar orthopedic implant market with a differentiated biomaterial approach.

Clinical Performance and Surgeon Feedback

Dr. Carrington reported positive initial results from the procedure, stating, "The implant performed exceptionally well and provided the structural integrity and imaging clarity that are critical in these cases. Silicon nitride is a compelling material because it combines mechanical performance with biologic interaction, which are key considerations in reconstructive surgery."

The silicon nitride technology offers several advantages over traditional metal and plastic implants, including osteoconductive and pro-osteogenic properties, bacteriostatic surface characteristics, hydrophilicity, and radiographic compatibility with X-ray, CT, and MRI imaging. These features may allow surgeons to better assess implant positioning and healing progression, potentially improving clinical decision-making during recovery.

Strategic Transformation and Leadership Changes

The clinical milestone comes as part of SINTX's broader strategic transformation throughout 2025 and early 2026. The company has executed several key initiatives to position itself for commercial growth, including divesting non-medical assets, recruiting a new Board of Directors with healthcare and medical device experience, and strengthening its balance sheet through approximately $10 million in capital raised.

On March 16, 2026, SINTX appointed Ryan Elmore as President to lead commercialization and strategic growth initiatives. Elmore brings more than 15 years of experience in advanced biomaterials and medical device commercialization, including prior leadership roles at Invibio (search)Search term, a division of Victrex plc (search)Search company.

"SINTX has already established a strong technical and clinical foundation," said Elmore. "Our focus now is execution—accelerating commercialization, expanding market access, and building scalable revenue opportunities across the Company's silicon nitride platform."

Platform Expansion and Manufacturing Evolution

Beyond the foot and ankle application, SINTX continues to advance its silicon nitride technology across multiple material formats, including powders, coatings, porous structures, and composite materials such as SiN/PEEK and SiN/PEKK. The company has executed a supply agreement with global leader Evonik Industries (search)Search term to support development of SiNERGY (search)Search drug silicon nitride/PEEK composite materials.

SINTX is transitioning from traditional subtractive ceramic manufacturing toward more scalable, digitally enabled production methods, including AI-assisted 3D manufacturing. The company has recently acquired new equipment and expanded its technical team with key hires focused on additive and advanced processing technologies.

The company has also initiated preclinical animal studies evaluating the incorporation of silicon nitride into sutures, meshes, and wound care materials. These studies are intended to explore the material's surface properties and potential applicability in soft tissue and wound management environments, with SINTX expecting to finalize preclinical data in the second half of 2026.

Market Opportunity and Future Outlook

Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies (search)Search company, emphasized the significance of this milestone: "This first-in-human procedure is a defining milestone for SINTX and a critical step in our commercialization strategy. We are now translating years of materials science innovation into real-world surgical applications. Entry into the foot and ankle market expands our addressable opportunity and positions silicon nitride as a differentiated biomaterial platform capable of driving future revenue growth and broader surgeon adoption."

The global foot and ankle reconstruction market represents a significant opportunity, and SINTX believes its silicon nitride technology offers differentiated characteristics that may support broader adoption across orthopedic applications. The company is focused on expanding surgeon adoption of its SINAPTIC system, developing U.S. distribution and channel partnerships, advancing OEM and private-label opportunities, and pursuing strategic collaborations.

Lisa Marie Del Re, Chief Commercial Officer, noted: "For surgeons, this represents access to a next-generation biomaterial. For patients, it reflects the potential benefits of a material engineered to support bone healing and reduce complications. From a commercial standpoint, this milestone is an important step toward broader market adoption of the SINAPTIC platform."

With thousands of medical devices implanted since 2008 and nearly two decades of peer-reviewed research, SINTX has established itself as a leader in high-performance biomaterials. The company maintains a broad patent portfolio across multiple jurisdictions and has received multiple NIH grants supporting development of 3D-printed silicon nitride/polymer implantable medical devices.